bioMérieux S.A (BIM) | Financial Analysis & Statements
bioMérieux S.A. | Large-cap | Healthcare
bioMérieux S.A. | Large-cap | Healthcare
Financial Overview
Latest Annual: 2024Income Metrics
Revenue
4.0B
Gross Profit
2.2B
55.66%
Operating Income
637.9M
16.03%
Net Income
425.1M
10.68%
EPS (Diluted)
€3.64
Balance Sheet Metrics
Total Assets
5.8B
Total Liabilities
1.6B
Shareholders Equity
4.2B
Debt to Equity
0.37
Cash Flow Metrics
Operating Cash Flow
419.4M
Free Cash Flow
321.5M
Revenue & Profitability Trend
bioMérieux S.A Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 4.0B | 3.7B | 3.6B | 3.4B | 3.1B |
| Cost of Goods Sold | 1.8B | 1.6B | 1.6B | 1.4B | 1.4B |
| Gross Profit | 2.2B | 2.1B | 2.0B | 2.0B | 1.8B |
| Operating Expenses | 1.6B | 1.5B | 1.4B | 1.2B | 1.2B |
| Operating Income | 637.9M | 568.9M | 625.7M | 844.0M | 612.4M |
| Pre-tax Income | 579.3M | 437.5M | 580.5M | 774.5M | 524.4M |
| Income Tax | 154.3M | 114.5M | 140.1M | 175.6M | 121.5M |
| Net Income | 425.1M | 322.8M | 440.5M | 598.2M | 402.7M |
| EPS (Diluted) | €3.64 | €3.01 | €3.82 | €5.06 | €3.41 |
Income Statement Trend
bioMérieux S.A Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | 2.5B | 2.2B | 2.2B | 2.2B | 1.7B |
| Non-Current Assets | 3.3B | 3.1B | 3.0B | 2.4B | 2.3B |
| Total Assets | 5.8B | 5.3B | 5.2B | 4.6B | 3.9B |
| Liabilities | |||||
| Current Liabilities | 1.1B | 1.1B | 1.1B | 955.9M | 924.0M |
| Non-Current Liabilities | 424.6M | 419.4M | 412.6M | 485.5M | 522.5M |
| Total Liabilities | 1.6B | 1.5B | 1.5B | 1.4B | 1.4B |
| Equity | |||||
| Total Shareholders Equity | 4.2B | 3.8B | 3.6B | 3.2B | 2.5B |
Balance Sheet Composition
bioMérieux S.A Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 425.1M | 322.8M | 440.5M | 598.2M | 402.7M |
| Operating Cash Flow | 419.4M | 149.0M | 276.6M | 573.7M | 369.5M |
| Investing Activities | |||||
| Capital Expenditures | -336.4M | -331.9M | -269.3M | -270.1M | -252.8M |
| Investing Cash Flow | -359.8M | -488.8M | -528.1M | -307.3M | -265.2M |
| Financing Activities | |||||
| Dividends Paid | -100.2M | -100.2M | -101.2M | -73.1M | -22.5M |
| Financing Cash Flow | -175.0M | -135.0M | -244.2M | -127.0M | -176.2M |
| Free Cash Flow | 321.5M | 107.1M | 188.4M | 534.6M | 305.3M |
Cash Flow Trend
bioMérieux S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
32.96
Forward P/E
26.32
Price to Book
3.37
Price to Sales
3.56
PEG Ratio
26.32
Profitability Ratios
Profit Margin
10.86%
Operating Margin
16.82%
Return on Equity
10.68%
Return on Assets
7.23%
Financial Health
Current Ratio
2.20
Debt to Equity
11.65
Beta
0.48
Per Share Data
EPS (TTM)
€3.65
Book Value per Share
€35.66
Revenue per Share
€33.80
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| bim | 14.2B | 32.96 | 3.37 | 10.68% | 10.86% | 11.65 |
| Eurofins Scientific | 10.6B | 28.48 | 2.56 | 7.71% | 5.85% | 67.05 |
| Lumibird S.A | 353.3M | 61.73 | 1.78 | 2.91% | 2.71% | 81.34 |
| Eurofins Cerep SAS | 103.9M | 14.33 | - | 10.49% | 17.67% | 0.46 |
| Klea Holding | 53.9M | 17.87 | 1.92 | 5.35% | 8.14% | 21.13 |
| Predilife S.A | 13.9M | - | - | -4,653.75% | 97.76% | -1.16 |
Financial data is updated regularly. All figures are in the company's reporting currency.